Key takeaways
Budesonide (Eohilia) and dupilumab (Dupixent) are both used to treat eosinophilic esophagitis (EoE), but they belong to different medication classes. Budesonide is a corticosteroid, while dupilumab is a monoclonal antibody. Budesonide is taken orally as a suspension, typically twice a day, and is specifically FDA-approved for EoE in people aged 11 and older. Dupilumab, on the other hand, is given as a subcutaneous injection and is approved for EoE in adults and children as young as 1 year old. It's also approved for several other conditions, such as asthma, eczema, and chronic obstructive pulmonary disease (COPD). Budesonide can cause side effects like respiratory infections and fungal infections in the mouth, while dupilumab may lead to injection site reactions and eye inflammation. Budesonide interacts with medications like ritonavir and erythromycin, whereas live vaccines should be avoided with dupilumab. Neither medication is available as a generic.
